Disc Medicine Inc (IRON)

$80.94 +3.58 (4.63%)
Market Cap 2.99B
Revenue (ttm) 0.00
Net Income (ttm) -109.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.05
Volume 436,300
Avg Vol 559,378
Day's Range N/A - N/A
Shares Out 37.75M
Stochastic %K 95%
Beta 0.87
Analysts Strong Sell
Price Target $121.67

Company Profile

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeost...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 674 9274
Address:
321 Arsenal Street, Suite 101, Watertown, United States
BillionerOfKing
BillionerOfKing Jan. 6 at 8:27 PM
$IRON Current Stock Price: $76.47 Contracts to trade: $75 IRON Jan 16 2026 Call Entry: $3.00 Exit: $4.37 ROI: 46% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Buyorsell4321
Buyorsell4321 Jan. 2 at 2:56 PM
$IRON This is the type of stock that gets bought out IMO. I think it will be takeover soon. Big pharma needs the pipeline as patents run out.
0 · Reply
CapitalVisionPilot
CapitalVisionPilot Dec. 27 at 7:26 AM
$IRON Expectations are resetting toward sustainable results, not one‑off wins. Competitive advantages must begin to appear in core metrics. Any deterioration in traction could reset expectations abruptly. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
justiceforb_85
justiceforb_85 Dec. 22 at 6:52 PM
$IRON I think bitopertin will likely still receive FDA approval. Value is there in DISC-0974 as well.
0 · Reply
Quantumup
Quantumup Dec. 22 at 11:32 AM
a/o Friday: BMO Capital reiterated $IRON Outperform/$120 Jefferies reiterated Buy/$154 TD Cowen reiterated Buy Stifel analyst reiterated Buy/$125 $CLVLY Mitsubishi Tanabe Pharma $NVS ABBV GERN $PTGX - $TAK Here's what the Analysts had to say on Friday:
0 · Reply
medguy
medguy Dec. 20 at 12:00 AM
Traded the bounce for small gains thanks $IRON $LW
0 · Reply
StocktwitsNews
StocktwitsNews Dec. 19 at 9:18 PM
Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’ $IRON $IWMW $EAOR https://stocktwits.com/news/equity/markets/disc-medicine-stock-slides-after-fda-fast-track-approval-doubts-surface/cLe0e2PREtd
0 · Reply
notreload_ai
notreload_ai Dec. 19 at 7:47 PM
$IRON shares fall after FDA official questions bitopertin's effectiveness for rare blood disorder, though analysts maintain buy ratings and approval pathway optimism. https://notreload.xyz/disc-medicine-stock-falls-13-on-fda-official-questions/
0 · Reply
S_Franconi
S_Franconi Dec. 19 at 5:06 PM
$IRON Schwab not allowing electronic buys, this is being manipulated by some entity
0 · Reply
S_Franconi
S_Franconi Dec. 19 at 5:02 PM
$IRON RSI 30, time to buy
0 · Reply
Latest News on IRON
Disc Medicine: RALLY-MF Data Validates Pipeline Optionality

Jan 5, 2026, 5:37 AM EST - 2 days ago

Disc Medicine: RALLY-MF Data Validates Pipeline Optionality

Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript

Dec 7, 2025, 2:33 PM EST - 4 weeks ago

Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Dec 6, 2025, 8:00 AM EST - 4 weeks ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Disc Medicine, Inc. (IRON) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 12:13 PM EST - 7 weeks ago

Disc Medicine, Inc. (IRON) Presents at Jefferies London Healthcare Conference 2025 Transcript

Disc Medicine, Inc. (IRON) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 18, 2025, 5:58 PM EST - 7 weeks ago

Disc Medicine, Inc. (IRON) Presents at Stifel 2025 Healthcare Conference Transcript

Disc Medicine to Participate in Upcoming Investor Conferences

Oct 31, 2025, 8:30 AM EDT - 2 months ago

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Oct 21, 2025, 12:14 AM EDT - 2 months ago

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder Value

Oct 20, 2025, 9:15 AM EDT - 2 months ago

Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder Value

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Oct 20, 2025, 7:00 AM EDT - 2 months ago

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Oct 20, 2025, 6:30 AM EDT - 2 months ago

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

Oct 17, 2025, 9:00 AM EDT - 2 months ago

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)

Sep 30, 2025, 8:30 AM EDT - 3 months ago

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)

Disc Medicine, Inc. (IRON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 4:39 PM EDT - 4 months ago

Disc Medicine, Inc. (IRON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Disc Medicine Appoints Nadim Ahmed to its Board of Directors

Jul 14, 2025, 8:30 AM EDT - 6 months ago

Disc Medicine Appoints Nadim Ahmed to its Board of Directors

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

Jun 12, 2025, 7:30 AM EDT - 7 months ago

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

May 14, 2025, 9:30 AM EDT - 8 months ago

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 8:00 AM EDT - 8 months ago

Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update

Disc Medicine: Forging Ahead In Hematology

Apr 9, 2025, 7:13 AM EDT - 9 months ago

Disc Medicine: Forging Ahead In Hematology

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 8:00 AM EST - 11 months ago

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Jan 22, 2025, 9:35 PM EST - 1 year ago

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Jan 22, 2025, 8:10 AM EST - 1 year ago

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

PRGS

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 21, 2025, 4:01 PM EST - 1 year ago

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Jan 21, 2025, 7:45 AM EST - 1 year ago

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Jan 20, 2025, 7:00 PM EST - 1 year ago

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

Jan 17, 2025, 4:00 PM EST - 1 year ago

Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Dec 9, 2024, 12:00 PM EST - 1 year ago

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Dec 8, 2024, 8:00 PM EST - 1 year ago

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Nov 8, 2024, 8:30 AM EST - 1 year ago

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

Nov 4, 2024, 7:50 AM EST - 1 year ago

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Nov 1, 2024, 4:01 PM EDT - 1 year ago

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

Oct 25, 2024, 1:00 PM EDT - 1 year ago

Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Jun 14, 2024, 1:26 PM EDT - 1 year ago

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Disc Medicine Announces Underwritten Offering of Common Stock

Jun 14, 2024, 8:03 AM EDT - 1 year ago

Disc Medicine Announces Underwritten Offering of Common Stock

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Jun 14, 2024, 7:30 AM EDT - 1 year ago

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Disc Medicine to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 9:00 AM EDT - 1 year ago

Disc Medicine to Participate in the Jefferies Global Healthcare Conference

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

May 14, 2024, 10:30 AM EDT - 1 year ago

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 8:00 AM EDT - 1 year ago

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)

Apr 2, 2024, 8:01 AM EDT - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)

HUM

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 21, 2024, 8:00 AM EDT - 1 year ago

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

Mar 6, 2024, 4:30 PM EST - 2 years ago

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

Feb 26, 2024, 8:30 AM EST - 2 years ago

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

FDA Grants Orphan Drug Designation to 9MW3011

Feb 20, 2024, 9:00 AM EST - 2 years ago

FDA Grants Orphan Drug Designation to 9MW3011

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Feb 20, 2024, 8:30 AM EST - 2 years ago

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Feb 9, 2024, 9:00 AM EST - 2 years ago

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

Feb 7, 2024, 8:00 AM EST - 2 years ago

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 5:00 PM EST - 2 years ago

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BillionerOfKing
BillionerOfKing Jan. 6 at 8:27 PM
$IRON Current Stock Price: $76.47 Contracts to trade: $75 IRON Jan 16 2026 Call Entry: $3.00 Exit: $4.37 ROI: 46% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Buyorsell4321
Buyorsell4321 Jan. 2 at 2:56 PM
$IRON This is the type of stock that gets bought out IMO. I think it will be takeover soon. Big pharma needs the pipeline as patents run out.
0 · Reply
CapitalVisionPilot
CapitalVisionPilot Dec. 27 at 7:26 AM
$IRON Expectations are resetting toward sustainable results, not one‑off wins. Competitive advantages must begin to appear in core metrics. Any deterioration in traction could reset expectations abruptly. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
justiceforb_85
justiceforb_85 Dec. 22 at 6:52 PM
$IRON I think bitopertin will likely still receive FDA approval. Value is there in DISC-0974 as well.
0 · Reply
Quantumup
Quantumup Dec. 22 at 11:32 AM
a/o Friday: BMO Capital reiterated $IRON Outperform/$120 Jefferies reiterated Buy/$154 TD Cowen reiterated Buy Stifel analyst reiterated Buy/$125 $CLVLY Mitsubishi Tanabe Pharma $NVS ABBV GERN $PTGX - $TAK Here's what the Analysts had to say on Friday:
0 · Reply
medguy
medguy Dec. 20 at 12:00 AM
Traded the bounce for small gains thanks $IRON $LW
0 · Reply
StocktwitsNews
StocktwitsNews Dec. 19 at 9:18 PM
Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’ $IRON $IWMW $EAOR https://stocktwits.com/news/equity/markets/disc-medicine-stock-slides-after-fda-fast-track-approval-doubts-surface/cLe0e2PREtd
0 · Reply
notreload_ai
notreload_ai Dec. 19 at 7:47 PM
$IRON shares fall after FDA official questions bitopertin's effectiveness for rare blood disorder, though analysts maintain buy ratings and approval pathway optimism. https://notreload.xyz/disc-medicine-stock-falls-13-on-fda-official-questions/
0 · Reply
S_Franconi
S_Franconi Dec. 19 at 5:06 PM
$IRON Schwab not allowing electronic buys, this is being manipulated by some entity
0 · Reply
S_Franconi
S_Franconi Dec. 19 at 5:02 PM
$IRON RSI 30, time to buy
0 · Reply
medguy
medguy Dec. 19 at 4:33 PM
Looking for bounce $IRON
0 · Reply
www_larval_com
www_larval_com Dec. 19 at 4:22 PM
Dufus here, $IRON has turned 4% higher to -16% (~1Mv) moments ago, 01/16 options, follow for more volatility.
1 · Reply
Arcides
Arcides Dec. 19 at 4:15 PM
$IRON worst day of the year on high volume can just mean profit taking...
0 · Reply
Arcides
Arcides Dec. 19 at 3:45 PM
$IRON ride over
0 · Reply
StockBraker
StockBraker Dec. 19 at 3:44 PM
$IRON WTF?? Why would this small sale cause such a huge reaction. https://www.tipranks.com/news/insider-trading/disc-medicine-insider-transaction-raises-eyebrows-on-wall-street-insider-trading
1 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 2:56 PM
Wells Fargo has adjusted their stance on Disc Medicine ( $IRON ), setting the rating to Overweight with a target price of 91 → 109.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 11:13 PM
$IRON Current Stock Price: $92.93 Contracts to trade: $95 IRON Dec 19 2025 Call Entry: $0.10 Exit: $0.15 ROI: 48% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
doodoodeity
doodoodeity Dec. 9 at 5:27 PM
$IRON grabbed some, small position on this
0 · Reply
Braindead83
Braindead83 Dec. 8 at 8:39 PM
$IRON honestly wtf, this should be way up. Wayyyy up. Buying opportunity before the wake-up call run
0 · Reply